DOCSLIB.ORG

Hyponatremia

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Hyponatremia 9/30/2010 JAMES S. KALUS, PHARM.D, BCPS (AQ-CARDIOLOGY) Senior Manager, Patient Care Services, Department of Pharmacy Services Henry Ford Hospital, Detroit, MI NO RELATIONSHIPS TO DISCLOSE J. HERBERT PATTERSON, PHARM.D, Professor of Pharmacy Research Professor of Medicine Vice Chair for Research and Graduate Education UNC Eshelman School of Pharmacy Friday, October 1, 2010 University of North Carolina, Chapel Hill, NC Advisory Board Member Otsuka America Pharmaceuticals Inc.* *Conflict was resolved through Peer Review Learning Objectives • Describe the underlying pathophysiology, risk factors, and risk stratification of hospitalized patients with hyponatremia • Identify the mechanisms in which hyponatremia PLEASE TAKE A MOMENT TO ANSWER comppglicates the management of chronic medical THE PRE-ACTIVITY TEST QUESTIONS conditions • Assess the pharmacists role and current treatment options for hyponatremia in the hospital setting. • Examine the role of vasopressin receptor antagonists in the management of hyponatremia in the hospitalized patient Hyponatremia • Most common electrolyte abnormality Hyponatremia can be • Associated with many systemic diseases caused by dilution from – Major: dilution of extracellular fluid retained water, or by – Minor: total body losses of sodium dltidepletion fltltfrom electrolyte • Acute vs. Chronic losses in excess of water – Often duration is difficult to determine 1 9/30/2010 Role of Vasopressin Role of Vasopressin • Vasopressin = ADH = antidiuretic hormone Nephron • Physiologic sodium/water balance – Thirst: stimulated by rise in osmolality H O • Osmoreceptors 2 Vasopressin – Water excretion: regulated by vasopressin H2O • Osmoreceptors H2O – ↑ Osmolality = ↑ vasopressin secretion = ↑ H2O reabsorption Vasopressin – ↓ Osmolality = ↓ vasopressin secretion = ↓ H2O reabsorption = V2 Receptors AVP regulation of water reabsorption from renal tubular cells Classification: Osmolality CollectingDuct Cell AQP3 Collecting duc • Hypotonic hyponatremia – Sodium directly related to osmolality H2O – Most cases Vasa recta Vasa ATP GTP AQP2 Exocytic • Isotonic/Hypertonic hyponatremia AVP Insertion t (Gs) cAMP – Pseudohyponatremia AVP V2 Receptor PKA – Non-sodium solutes increase osmolality H2O AQP2 • Glucose • ↑ osmolality Æ fluid shifts Æ dilution of sodium Recycling Endocytic vesicle Retrieval AQP4 Basolateral Luminal membrane membrane Prevalence of dysnatremias at initial Classification: Volume Status presentation to a health care provider (data from 303,577 samples on 120,137 patients available for analysis) HYPONATREMIA HYPOVOLEMIC EUVOLEMIC HYPERVOLEMIC Na+ Loss Non-Physiologic ↑ Volume Release of ADH Diuretics Heart Failure SIADH Mineralocorticoid Liver Disease Deficiency Kidney Disease Glucosuria Ketonuria Vomiting Diarrhea Adapted from: Hawkins RC. Clin Chim Acta..2003; 337(1-2):169-72. 2 9/30/2010 Drug-Related Causes Risk Stratification Sodium Loss • Acute vs. Chronic • Diuretics – Acute = less than 48 hours in duration • Concerned about neurologic sequellae – Osmotic differential between brain and blood – Brain swelling ↑ Vasopressin/ADH effects – Chronic = greater than 48 hours in duration • Symptoms may be more modest • Antipsychotics – Brain has time to adapt • Antidepressants • Duration of hyponatremia • DDAVP – How aggressive? • Oxytocin – How fast? Discussion Question Discussion Question - ANSWER Common symptoms of chronic Common symptoms of chronic hyponatremia include fatigue, nausea, hyponatremia include fatigue, nausea, dizziness, lethargy, confusion, and gait dizziness, lethargy, confusion, and gait disturbances? disturbances? A. True A. True B. False B. False Symptomatic Hyponatremia: Symptoms Associated with Chronic Neurological Manifestations Hyponatremia 223 consecutive hospitalized patients with symptomatic • Headache hyponatremia ([Na+] 98 to 128 mmol/l) due to thiazides • Irritability • Malaise/Lethargy: 109 (49%) Nausea/Vomiting • Chronic • Dizzy Spells: 104 (47%) 223/223 resolved Mental Slowing symptoms with • • Vomiting: 77 (35%) correction of [Na+] • Confusion/Delirium • Confusion/Obtundation: 39 (17%) via cessation of thiazide treatment • Disorientation • Falls: 37 (17%) • Headache: 13 (6%) • Stupor/Coma • Seizures: 2 (0.9%) • Convulsions Acute • Respiratory Arrest Chow KM, et al. J Natl Med Assoc. 2004; 96:1305-1309. 3 9/30/2010 Increased Risk of Falls with Sodium and the Brain “Asymptomatic” Hyponatremia Na+ moves from high concentrations to low Adjusted + Odds Water follows Na Group n Falls Odds Ratio Time-dependent Ratio* 9.45 67.43 + + “Asymptomatic”Chronic + 122 21.3% (2.64-34.09) (7.48-607.42) + Hyponatremia + p <.001 p <.001 + + + + + Normonatremic controls 244 5.35% 1.00 1.00 + + + + + + + + + *adjusted for age, sex and covariates BRAIN EDEMA Adapted from: Renneboog B, et al. Am J Med. 2006;119(1): 71. e1-8. Reductions of Brain Organic Osmolytes after 14 days of Sustained Hyponatremia Discussion Question The hyponatremic brain is NOT a normal brain, but rather There is less likelihood of rapid fluid represents a state of allostasis -30% as a result of solute losses shifts and brain edema in cases of acute hyponatremia than there are in cases ofhf chron ihic hypona trem ia A. True B. False *P < 0.01 compared to normonatremic control rats. Adapted from: Verbalis JG, et al. Brain Res. 1991; 567(2):274-82. Discussion Question - ANSWER Acute vs. Chronic and the Brain There is less likelihood of rapid fluid • Acute hyponatremia shifts and brain edema in cases of – Rapid onset acute hyponatremia than there are in – Greater likelihood of rapid fluid shifts and brain edema cases ofhf chron ihic hypona trem ia • Chronic hyponatremia A. True – Insidious onset B. False – Less likelihood for brain edema • Time for compensatory increases in organic osmolytes 4 9/30/2010 How Aggressive? How Fast? Sodium and the Brain LEVEL 3 - SEVERE SYMPTOMS: Na+ moves from high concentrations to low vomiting, seizures, obtundation, Emergency! Correct RAPIDLY Water follows Na+ respiratory distress, coma Implications for treatment LEVEL 2 - MODERATE + + + SYMPTOMS: + nausea, confusion, disorientation, + altered mental status + ++ + + + + + LEVEL 1 - NO OR MINIMAL + + SYMPTOMS: + headache, irritability, inability to OK to correct more slowly concentrate, altered mood, depression Rapid fluid shifts out of the brain: OSMOTIC DEMYELINATION Implications of Hyponatremia Heart failure • There are an estimated 7 million Americans with Hyponatremia HF (2% of US population). and Heart Failure • Hyponatremia is one of the newer and emerging risk factors for an adverse prognosis in chronic heart failure • Increased release of vasopressin may result in excess fluid retention and hyponatremia. Implications of Hyponatremia Liver Disease • Associated with poor prognosis & reduced Hyponatremia survival • Impairs the management of ascites and Liver Disease • Predisposes to hepatic encephalopathy • Impairs quality of life 5 9/30/2010 Pathogenesis of Hyponatremia in Cirrhosis Distribution of serum sodium in patients Systemic arterial vasodilatation with liver cirrhosis & ascites (n=983) Sinusoidal portal hypertension Severe liver dysfunction % Hyperdynamic ↑total body blood volume, but circulation ++ 40 ↓↓EABV 35.1 35 27.9 ActActivationivation ooff RAARAASS & SSNSNS ++ 30 Diuretic responsive Non-osmotic release of vasopressin ↓ 25 Diuretic resistant 20 15.8 15 11.1 Severe renal Na retention 10 proximal > distal tubular 4.5 4.4 5 1.3 Water retention follows Na retention 0 </=120 121-125 126-130 131-135 136-140 141-145 >145 serum sodium (mEq/L) When water retention> Na retention, hyponatremia develops Adapted from P.Angeli et al. Hepatology 2006; 44:1535-1542 Serum Sodium and Mortality Liver Transplant candidates in the VA system, 97-03 (n= 507) ̵ Hepatitis C (68%), EtOH (67%) ̵ MELD 16.2 + 6.7 ̵ Hyponatremia (<130 mEq/L): 31% ̵ Persistent Ascites/Hydrothorax: 38% Syndrome of inappropriate • Predictors of 6-month mortality antidiuretic hormone (()SIADH) Odds Ratio p secretion MELD 1.25 (1.16-1.35) <0.001 Na < 135 mEq/L 2.76 (1.31-5.81) 0.008 Persistent 2.72 (1.31-5.71) 0.008 Ascites Heuman DM, et al. Hepatology. 2004;40(4):802-10. Syndrome of Inappropriate Anti-diuretic Causes of Syndrome of Inappropriate Hormone (SIADH): Essential Criteria Anti-diuretic Hormone (SIADH): Pulmonary Disorders Tumors CNS Disorders Acute respiratory failure Extrathoracic Acute psychosis • True plasma hypoosmolality Infections Mediastinal Hemorrhage Positive-pressure ventilation Pulmonary Inflammatory and Urine concentration inappropriate for plasma demyelinating diseases • Mass lesions Stroke osmolality (Uosm > 100 mOsm/kg H2O) SIADH Trauma • Clinical euvolemia, no diuretic therapy Drugs • Absent renal sodium conservation (UNa > 30 Carbamazepine Phenothiazines Miscellaneous Chlorpropamide Prostaglandin-synthesis HIV infection mmol/L) Clofibrate inhibitors Idiopathic Cyclophosphamide SSRIs Pain Desmopressin MAO inhibitors Postoperative state • Normal thyroid, adrenal and renal function Nicotine Tricyclics Prolonged exercise Oxytocin Vincristine Senile atrophy Opiates Severe nausea Bartter FC, et al. Am J Med. 1967; 42:790-806. 6 9/30/2010 Conclusions – Hyponatremia is a common disorder of electrolytes seen in the hospital setting. – Acute severe hyponatremia can cause substantial morbidity and mortality, particularly in patients with co morbidities. – Overly rapid correction of chronic hyponatremia can cause severe neurologic deficits and death. – SIADH is the most common cause of euvolemic hyponatremia in clinical medicine. – Hypervolemic
Load more

Recommended publications
  • The Science of Medicine. the Art of Healing. Going Lecture Free for Genz
    The science of medicine. The art of healing. Going Lecture Free for GenZ Brenda J.B. Roman, M.D. Associate Dean for Medical Education Irina Overman, M.D. Director of Foundations Curriculum Mary Jo Trout, Pharm.D. Director of Therapeutics Curriculum Image obtained from: https://visual.ly/community/infographic/other/generation-z Gen Z Learning Preferences ▪ “Hands on” learning opportunities ▪ Application to “real Life” ▪ Desire community engagement ▪ “Observers” first ▪ Value independent learning ▪ Differs from Millennials (teamwork-oriented approach) ▪ View peers and instructors as valuable resources No attendance problems What we did… Science of Learning Research… What doesn’t work Cognitive illusions ▪ Ineffective strategies that produce massive overconfidence Popular ineffective strategies ▪ Passive repetitive reading ▪ Highlighting and underlining ▪ Summarization ▪ Keyword mnemonics ▪ Imagery for text Science of Learning Research… What does work ▪ Interleaved practice ▪ Elaborative interrogation ▪ Self-explanation ▪ Distributed practice ▪ Practice testing ▪ Retrieval-based learning Foster a Growth Mindset ➢ Willingness to learn ➢ Get comfortable with from reading less than full mastery of material before the session Peer Multiple-Choice Instruction Questions Team-Based WrightQ Learning WrightCurriculum DISTRIBUTED PRACTICE INTERLEAVING READING Peer Instruction Students answer problem sets individually with ARS, then peer instruct and re-answer individually Retrieval-based learning Elaborative interrogation Self-explanation Practice
    [Show full text]
  • AHFS Pharmacologic-Therapeutic Classification System
    AHFS Pharmacologic-Therapeutic Classification System Abacavir 48:24 - Mucolytic Agents - 382638 8:18.08.20 - HIV Nucleoside and Nucleotide Reverse Acitretin 84:92 - Skin and Mucous Membrane Agents, Abaloparatide 68:24.08 - Parathyroid Agents - 317036 Aclidinium Abatacept 12:08.08 - Antimuscarinics/Antispasmodics - 313022 92:36 - Disease-modifying Antirheumatic Drugs - Acrivastine 92:20 - Immunomodulatory Agents - 306003 4:08 - Second Generation Antihistamines - 394040 Abciximab 48:04.08 - Second Generation Antihistamines - 394040 20:12.18 - Platelet-aggregation Inhibitors - 395014 Acyclovir Abemaciclib 8:18.32 - Nucleosides and Nucleotides - 381045 10:00 - Antineoplastic Agents - 317058 84:04.06 - Antivirals - 381036 Abiraterone Adalimumab; -adaz 10:00 - Antineoplastic Agents - 311027 92:36 - Disease-modifying Antirheumatic Drugs - AbobotulinumtoxinA 56:92 - GI Drugs, Miscellaneous - 302046 92:20 - Immunomodulatory Agents - 302046 92:92 - Other Miscellaneous Therapeutic Agents - 12:20.92 - Skeletal Muscle Relaxants, Miscellaneous - Adapalene 84:92 - Skin and Mucous Membrane Agents, Acalabrutinib 10:00 - Antineoplastic Agents - 317059 Adefovir Acamprosate 8:18.32 - Nucleosides and Nucleotides - 302036 28:92 - Central Nervous System Agents, Adenosine 24:04.04.24 - Class IV Antiarrhythmics - 304010 Acarbose Adenovirus Vaccine Live Oral 68:20.02 - alpha-Glucosidase Inhibitors - 396015 80:12 - Vaccines - 315016 Acebutolol Ado-Trastuzumab 24:24 - beta-Adrenergic Blocking Agents - 387003 10:00 - Antineoplastic Agents - 313041 12:16.08.08 - Selective
    [Show full text]
  • Conivaptan (Vaprisol )
    January 3, 2007 Conivaptan (Vaprisol ®) DESCRIPTION WHAT YOU MAY NOT BE TOLD Conivaptan (Vaprisol ®) is an inhibitor of arginine Conivaptan is currently approved for euvolemic vasopressin that prevents its binding to V1a and V2 hyponatremia, but the only peer-reviewed published receptors located within the vasculature and renal data is in acute exacerbations of heart failure. It is tubules, respectively. Conivaptan was approved likely that the drug manufacturer will pursue this December 30, 2005, and is a first-in-class agent indication in the future. Conivaptan is also a potent approved for euvolemic hyponatremia. Conivaptan is inhibitor of CYP 3A4 and, as an oral formulation, available in 20 mg/5mL glass ampules. increases the area under the curve of midazolam 2- to 3-fold, simvastatin 3-fold, and amlodipine 2-fold. This WHAT THE PHARMACIST SHOULD KNOW level of interaction is what prevented the oral Euvolemic hyponatremia is most commonly associated formulation from being pursued for FDA approval. with the syndrome of inappropriate antidiuretic hormone secretion (SIADH). Causes of this syndrome WHAT THE PATIENT SHOULD KNOW include pulmonary disease (e.g., pneumonia, Conivaptan is used to treat euvolemic hyponatremia, tuberculosis, pleural effusion) and CNS disease (e.g., manifested when a patient has too little sodium in the tumor, subarachnoid hemorrhage, meningitis). SIADH bloodstream but a normal amount of fluid in the body. also occurs with malignancies (e.g., small cell Conivaptan should not be used at this time for heart carcinoma of the lung) and can be caused by drugs failure. Conivaptan has relatively few adverse effects (e.g., chlorpropamide, carbamazepine, narcotic and is well tolerated.
    [Show full text]
  • DDAVP Nasal Spray Is Provided As an Aqueous Solution for Intranasal Use
    DDAVP® Nasal Spray (desmopressin acetate) Rx only DESCRIPTION DDAVP® Nasal Spray (desmopressin acetate) is a synthetic analogue of the natural pituitary hormone 8-arginine vasopressin (ADH), an antidiuretic hormone affecting renal water conservation. It is chemically defined as follows: Mol. wt. 1183.34 Empirical formula: C46H64N14O12S2•C2H4O2•3H2O 1-(3-mercaptopropionic acid)-8-D-arginine vasopressin monoacetate (salt) trihydrate. DDAVP Nasal Spray is provided as an aqueous solution for intranasal use. Each mL contains: Desmopressin acetate 0.1 mg Sodium Chloride 7.5 mg Citric acid monohydrate 1.7 mg Disodium phosphate dihydrate 3.0 mg Benzalkonium chloride solution (50%) 0.2 mg The DDAVP Nasal Spray compression pump delivers 0.1 mL (10 mcg) of DDAVP (desmopressin acetate) per spray. CLINICAL PHARMACOLOGY DDAVP contains as active substance desmopressin acetate, a synthetic analogue of the natural hormone arginine vasopressin. One mL (0.1 mg) of intranasal DDAVP has an antidiuretic activity of about 400 IU; 10 mcg of desmopressin acetate is equivalent to 40 IU. 1. The biphasic half-lives for intranasal DDAVP were 7.8 and 75.5 minutes for the fast and slow phases, compared with 2.5 and 14.5 minutes for lysine vasopressin, another form of the hormone used in this condition. As a result, intranasal DDAVP provides a prompt onset of antidiuretic action with a long duration after each administration. 1 2. The change in structure of arginine vasopressin to DDAVP has resulted in a decreased vasopressor action and decreased actions on visceral smooth muscle relative to the enhanced antidiuretic activity, so that clinically effective antidiuretic doses are usually below threshold levels for effects on vascular or visceral smooth muscle.
    [Show full text]
  • Spray Desmopressin Acetate Nasal Spray 10 Μg/Spray
    PRODUCT MONOGRAPH Pr DDAVP® Spray Desmopressin Acetate Nasal Spray 10 µg/spray Pr DDAVP® Rhinyle Desmopressin Acetate Nasal Solution 0.1 mg/mL Antidiuretic Ferring Inc. Date of Revision: 200 Yorkland Blvd, Suite 800 June 19, 2008 North York, Ontario M2J 5C1 Submission Control No: 119073 DDAVP® Spray and Rhinyle Page 1 of 23 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION.........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE..............................................................................3 WARNINGS AND PRECAUTIONS..................................................................................4 ADVERSE REACTIONS....................................................................................................6 DRUG INTERACTIONS ....................................................................................................7 DOSAGE AND ADMINISTRATION................................................................................7 OVERDOSAGE ..................................................................................................................9 ACTION AND CLINICAL PHARMACOLOGY ..............................................................9 STORAGE AND STABILITY..........................................................................................11 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................11 PART II: SCIENTIFIC INFORMATION
    [Show full text]
  • Subject: Samsca (Tolvaptan) Original Effective Date: 07/27/15
    Subject: Samsca (tolvaptan) Original Effective Date: 07/27/15 Policy Number: MCP-252 Revision Date(s): Review Date(s): 12/15/2016; 6/22/2017 DISCLAIMER This Medical Policy is intended to facilitate the Utilization Management process. It expresses Molina's determination as to whether certain services or supplies are medically necessary, experimental, investigational, or cosmetic for purposes of determining appropriateness of payment. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered (i.e., will be paid for by Molina) for a particular member. The member's benefit plan determines coverage. Each benefit plan defines which services are covered, which are excluded, and which are subject to dollar caps or other limits. Members and their providers will need to consult the member's benefit plan to determine if there are any exclusion(s) or other benefit limitations applicable to this service or supply. If there is a discrepancy between this policy and a member's plan of benefits, the benefits plan will govern. In addition, coverage may be mandated by applicable legal requirements of a State, the Federal government or CMS for Medicare and Medicaid members. CMS's Coverage Database can be found on the CMS website. The coverage directive(s) and criteria from an existing National Coverage Determination (NCD) or Local Coverage Determination (LCD) will supersede the contents of this Molina Clinical Policy (MCP) document and provide the directive for all Medicare members. SUMMARY OF EVIDENCE/POSITION This policy addresses the coverage of Samsca (tolvaptan) for the treatment of clinically significant hypervolemic and euvolemic hyponatremia when appropriate criteria are met.
    [Show full text]
  • Oxytocin Regulates the Expression of Aquaporin 5 in the Latepregnant Rat
    RESEARCH ARTICLE Molecular Reproduction & Development 81:524–530 (2014) Oxytocin Regulates the Expression of Aquaporin 5 in the Late-Pregnant Rat Uterus ESZTER DUCZA,* ADRIENN B. SERES, JUDIT HAJAGOS-TOTH, GEORGE FALKAY, AND ROBERT GASPAR Department of Pharmacodynamics and Biopharmacy, Faculty of Pharmacy, University of Szeged, Szeged, Hungary SUMMARY Aquaporins (AQPs) are integral membrane channels responsible for the transport of water across a cell membrane. Based on reports that AQPs are present and accumulate in the female reproductive tract late in pregnancy, our aim was to study the expression of AQP isoforms (AQP1, 2, 3, 5, 8, and 9) at the end of pregnancy in rat in order to determine if they play a role in parturition. Reverse-transcriptase PCR revealed that specific Aqp mRNAs were detectable in the myometrium of non- pregnant and late-pregnancy (Days 18, 20, 21, and 22 of pregnancy) rat uteri. The expression of Aqp5 mRNA and protein were most pronounced on Days 18À21, and were dramatically decreased on Day 22 of pregnancy. In contrast, a significant increase was found in the level of Aqp5 transcript in whole-blood samples ÃCorresponding author: on the last day of pregnancy.The effect of oxytocin on myometrial Aqp5 expression in Department of Pharmacodynamics an organ bath was also investigated. The level of Aqp5 mRNA significantly decreased and Biopharmacy À8 University of Szeged, H-6720 5 min after oxytocin (10 M) administration, similarly to its profile on the day of Eotv€ os€ u. 6, Szeged 6270 delivery; this effect was sensitive to the oxytocin antagonist atosiban. The vasopres- Hungary.
    [Show full text]
  • Management and Treatment of Lithium-Induced Nephrogenic Diabetes Insipidus
    REVIEW Management and treatment of lithium- induced nephrogenic diabetes insipidus Christopher K Finch†, Lithium carbonate is a well documented cause of nephrogenic diabetes insipidus, with as Tyson WA Brooks, many as 10 to 15% of patients taking lithium developing this condition. Clinicians have Peggy Yam & Kristi W Kelley been well aware of lithium toxicity for many years; however, the treatment of this drug- induced condition has generally been remedied by discontinuation of the medication or a †Author for correspondence Methodist University reduction in dose. For those patients unresponsive to traditional treatment measures, Hospital, Department several pharmacotherapeutic regimens have been documented as being effective for the of Pharmacy, University of management of lithium-induced diabetes insipidus including hydrochlorothiazide, Tennessee, College of Pharmacy, 1265 Union Ave., amiloride, indomethacin, desmopressin and correction of serum lithium levels. Memphis, TN 38104, USA Tel.: +1 901 516 2954 Fax: +1 901 516 8178 [email protected] Lithium carbonate is well known for its wide use associated with a mutation(s) of vasopressin in bipolar disorders due to its mood stabilizing receptors. Acquired causes are tubulointerstitial properties. It is also employed in aggression dis- disease (e.g., sickle cell disease, amyloidosis, orders, post-traumatic stress disorders, conduct obstructive uropathy), electrolyte disorders (e.g., disorders and even as adjunctive therapy in hypokalemia and hypercalcemia), pregnancy, or depression. Lithium has many well documented conditions induced by a drug (e.g., lithium, adverse effects as well as a relatively narrow ther- demeclocycline, amphotericin B and apeutic range of 0.4 to 0.8 mmol/l. Clinically vincristine) [3,4]. Lithium is the most common significant adverse effects include polyuria, mus- cause of drug-induced nephrogenic DI [5].
    [Show full text]
  • Vasopressin V2 Is a Promiscuous G Protein-Coupled Receptor That Is Biased by Its Peptide Ligands
    bioRxiv preprint doi: https://doi.org/10.1101/2021.01.28.427950; this version posted January 28, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Vasopressin V2 is a promiscuous G protein-coupled receptor that is biased by its peptide ligands. Franziska M. Heydenreich1,2,3*, Bianca Plouffe2,4, Aurélien Rizk1, Dalibor Milić1,5, Joris Zhou2, Billy Breton2, Christian Le Gouill2, Asuka Inoue6, Michel Bouvier2,* and Dmitry B. Veprintsev1,7,8,* 1Laboratory of Biomolecular Research, Paul Scherrer Institute, 5232 Villigen PSI, Switzerland and Department of Biology, ETH Zürich, 8093 Zürich, Switzerland 2Department of Biochemistry and Molecular medicine, Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, Québec, Canada 3Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA 94305, USA 4The Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, 97 Lisburn Road, Belfast, BT9 7BL, United Kingdom 5Department of Structural and Computational Biology, Max Perutz Labs, University of Vienna, Campus-Vienna-Biocenter 5, 1030 Vienna, Austria 6Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Miyagi 980-8578, Japan. 7Centre of Membrane Proteins and Receptors (COMPARE), University of Birmingham and University of Nottingham, Midlands, UK. 8Division of Physiology, Pharmacology & Neuroscience, School of Life Sciences, University of Nottingham, Nottingham, NG7 2UH, UK. *Correspondence should be addressed to: [email protected], [email protected], [email protected].
    [Show full text]
  • Diuretics in Clinical Practice. Part I: Mechanisms of Action, Pharmacological Effects and 1
    Review Diuretics in clinical practice. Part I: mechanisms of action, pharmacological effects and 1. Introduction clinical indications of diuretic 2. Principles of diuretic action and classification of diuretic compounds compounds † 3. Carbonic anhydrase inhibitors Pantelis A Sarafidis , Panagiotis I Georgianos & Anastasios N Lasaridis Aristotle University of Thessaloniki, AHEPA Hospital, Section of Nephrology and Hypertension, 4. Osmotic diuretics 1st Department of Medicine, Thessaloniki, St. Kiriakidi 1, 54636, Thessaloniki, Greece 5. Loop diuretics 6. Thiazides and thiazide-related Importance of the field: Diuretics are among the most important drugs of our diuretics therapeutic armamentarium and have been broadly used for > 50 years, 7. Potassium-retaining diuretics providing important help towards the treatment of several diseases. Although all diuretics act primarily by impairing sodium reabsorption in the renal 8. Conclusion tubules, they differ in their mechanism and site of action and, therefore, in 9. Expert opinion their specific pharmacological properties and clinical indications. Loop diure- tics are mainly used for oedematous disorders (i.e., cardiac failure, nephrotic syndrome) and for blood pressure and volume control in renal disease; thiazides and related agents are among the most prescribed drugs for hypertension treatment; aldosterone-blockers are traditionally used for primary or secondary aldosteronism; and other diuretic classes have more specific indications. Areas covered in this review: This article discusses the mechanisms of action, pharmacological effects and clinical indications of the various diuretic classes For personal use only. used in everyday clinical practice, with emphasis on recent knowledge sug- gesting beneficial effects of certain diuretics on clinical conditions distinct from the traditional indications of these drugs (i.e., heart protection for aldosterone blockers).
    [Show full text]
  • Mineralocorticoid Receptor Antagonists for Heart Failure with Reduced Ejection Fraction: Integrating Evidence Into Clinical Practice
    European Heart Journal Advance Access published August 31, 2012 European Heart Journal REVIEW doi:10.1093/eurheartj/ehs257 Novel Therapeutic Concepts Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice Faiez Zannad1*, Wendy Gattis Stough2,PatrickRossignol1, Johann Bauersachs3, John J.V. McMurray4,KarlSwedberg5,AllanD.Struthers6, Adriaan A. Voors7, Luis M. Ruilope8,GeorgeL.Bakris9, Christopher M. O’Connor10, Mihai Gheorghiade11, Downloaded from Robert J. Mentz10, Alain Cohen-Solal12,AldoP.Maggioni13, Farzin Beygui14, Gerasimos S. Filippatos15,ZiadA.Massy16, Atul Pathak17, Ileana L. Pin˜a18, Hani N. Sabbah19, Domenic A. Sica20, Luigi Tavazzi21, and Bertram Pitt22 http://eurheartj.oxfordjournals.org/ 1INSERM, Centre d’Investigation Clinique 9501 and Unite´ 961, Centre Hospitalier Universitaire, and the Department of Cardiology, Nancy University, Universite´ de Lorraine, Nancy, France; 2Campbell University College of Pharmacy and Health Sciences, Buies Creek, NC, USA; 3Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany; 4Western Infirmary and the British Heart Foundation, Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK; 5Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; 6University of Dundee, Ninewells Hospital and Medical School, Dundee, UK; 7University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; 8Hypertension
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]